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Abstract: The purpose was to obtain a reliable scoring for growth of unruptured intracranial
aneurysms (UIAs) in a long-term follow-up study from variables known at baseline and to compare
it with the ELAPSS (Earlier subarachnoid hemorrhage, Location of the aneurysm, Age > 60 years,
Population, Size of the aneurysm, and Shape of the aneurysm) score obtained from an individual-based
meta-analysis. The series consists of 87 patients with 111 UIAs and 1669 person-years of follow-up
between aneurysm size measurements (median follow-up time per patient 21.7, range 1.2 to 51.0 years).
These were initially diagnosed between 1956 and 1978, when UIAs were not treated in our country.
ELAPSS scores at baseline did not differ between those with and those without aneurysm growth.
The area under the curve (AUC) for the receiver operating curve (ROC) of the ELAPSS score for
predicting long-term growth was fail (0.474, 95% CI 0.345–0.603), and the optimal cut-off point was
obtained at ≥7 vs. <7 points for sensitivity (0.829) and specificity (0.217). In the present series UIA
growth was best predicted by female sex (4 points), smoking at baseline (3 points), and age <40 years
(2 points). The AUC for the ROC of the new scoring was fair (0.662, 95% CI 0.546–0.779), which was
significantly better than that of ELAPSS score (p < 0.05). The optimal cut-off point was obtained at ≥4
vs. <4 points for sensitivity (0.971) and specificity (0.304). A new simple scoring consisting of only
female sex, cigarette smoking and age <40 years predicted growth of an intracranial aneurysm in
long-term follow-up, significantly better than the ELAPSS score.
Keywords: unruptured intracranial aneurysm; natural history; cigarette smoking; risk factors;
aneurysm growth; subarachnoid hemorrhage
1. Introduction
Subarachnoid hemorrhage (SAH) is a serious disease with a high rate of unfavorable outcomes [1–4].
The rate of treatment of unruptured aneurysms (UIAs) has been increased with a purpose to reduce
incidence of SAH [4–6]. However, the effect of treating UIAs on the incidence SAH has been low [7],
compared with that of reducing the prevalence of smoking [7,8]. In any case, the majority of diagnosed
UIAs never rupture during the remainder of the patient’s lifetime even in the case of patients of
working age [9,10].
Since the prevalence of aneurysms is not decreasing [11], the risk of rupture is likely decreasing,
resulting in lower SAH incidence rates [7,8]. The indications for treatment of UIAs are already
challenging because of a lack of prospective studies of natural history of UIAs [12]. Since such studies
are not possible to complete nowadays without treatment selection, interest has been focused on studies
of aneurysm growth, assuming this to be an important prognostic factor for aneurysm rupture [13–15].
Most UIA growth studies have also been derived from patient populations with treatment selection
bias with low rupture rates. UIA growth has been shown to increase risk of aneurysm rupture [14,15].
According to two recent meta-analyses of aneurysm growth, female sex, cigarette smoking at
baseline, aneurysm size, posterior circulation aneurysms, and possibly age, hypertension, and aneurysm
J. Clin. Med. 2020, 9, 3339; doi:10.3390/jcm9103339 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 3339 2 of 10
multiplicity may increase the risk of UIA growth, while prior SAH and a family history of aneurysms
do not [13,14]. Aneurysm growth rates were lower in prospective and high-quality studies [13].
A large meta-analysis of individual data from 1507 patients in 10 cohorts showed UIA growth
in 257 cases (17%) during 5782 patient-years of follow-up [16]. Predictors for aneurysm growth
during a mean follow-up of 3.8 years were Earlier SAH (decreased risk), Location of the aneurysm,
Age >60 years, Population, and Sze and Shape of the aneurysm (ELAPSS score). The 3-year growth
rate ranged between <5% and >42% and the 5-year growth rate between <9% and >60%, depending
on the risk factors. The results between ELAPSS score and previous meta-analyses differed between
each other for sex, age, previous SAH, populations, and some aneurysm locations. Cigarette smoking
was not studied in the ELAPSS study. Most of the cohorts were from selected populations where the
patients with UIAs were those left for conservative follow-up because of an estimated low rupture risk,
or a limited life expectancy or high treatment risks [16]. UIA may, however, be unchanged >20 years,
then grow a little and rupture [15,17,18].
An almost lifelong follow-up cohort of UIAs [9,15] seen at our institution was not subject to
treatment selection bias and had been considered to be the highest quality study and to have the least
source of bias of any prospective natural history studies of both UIA rupture and growth [12–14].
The aim here is to investigate the validity of the ELAPSS score in predicting the long-term UIA growth
risk and to search for a new score from variables known at baseline which could better predict the UIA
growth rate.
2. Methods
2.1. Patient Population
Approval for the surveys and follow-up data collection was obtained from the local ethics
committee (the ethics committee of the Department of Neurosurgery, Helsinki University Central
Hospital, Helsinki, Finland; the record 6/94; 29 December 1994) and all aspects of the study were in
compliance with national legislation and the Declaration of Helsinki [9]. All the patients gave their
written informed consent.
The series comprised of 87 patients with UIAs diagnosed at the Department of Neurosurgery
of Helsinki University Central Hospital between 1956 and 1978, when UIAs were not operated on
in Finland and when this hospital was responsible for neurosurgical services for almost the whole
Finnish population [1,9,10,15,17,18]. The series included patients with angiographic follow-up and
also those whose aneurysms were measured at autopsy, since aneurysm size is known be associated
with both aneurysm rupture and case fatality after SAH [1,15,17].
2.2. Age and Sex Distributions of Patients with and without Follow-Up Monitoring
Of the 142 patients with UIAs diagnosed before 1979, 56 patients were studied in the outpatient
department during 1996–1998 [15,17]. Only 4 patients with UIAs who were alive and had not been
examined previously with control angiography failed to visit the outpatient department for CT
angiography [17]. These patients were elderly (>80 years) and/or had a severe incapacitating disease
and were accordingly excluded from the study.
In addition, the aneurysm sizes of 43 patients were monitored with conventional or digital
angiography (n = 33) or at autopsy (n = 10) between 1959 and 2008 because of an aneurysm rupture or
a need to check the aneurysm status. The last follow-up was performed in 2012.
Since the cohort included patients who were admitted during a time period of 22 years (1956–1978),
there were a further 51 patients with UIAs who had already died without a control angiography, vast
majority of them from unrelated causes [15,17,18]. As was to be expected, these patients who were
excluded without a control examination of their UIA (55 out of 142) differed from those in the present
cohort by their higher age at baseline (mean ± SD, 47.1 ± 9.2 vs. 38.4 ± 9.1 years, p < 0.001).
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2.3. Follow-Up Methods
Detailed follow-up protocols have been reported previously [1,9,10,15,17–21]. Briefly, the follow-up
evaluations with reports were based on postal questionnaires and telephone interviews obtained from
patients or proxies every 10 years from the 1960s onwards. In total, 56 patients were additionally studied
in the outpatient department during 1996–1998 [15,17]. I personally interviewed the patients with the
use of a structured questionnaire, and their cerebral vessels were studied with 3D CT angiography (CTA).
The structured questionnaire through the follow-up included patient characteristics, previous diseases,
hospital visits, medication, and health behavior.
Additional information on all the patients was obtained from medical records supplied by other
hospitals and general practitioners, and the accuracy of the medical data including blood pressure (BP)
values was recorded [1,9,10,15,17,19]. Autopsy reports and official death certificates were examined
for all deceased patients. In Finland, a statutory medico-legal autopsy is performed on all those who
die due to trauma or unknown causes (Act on Inquests into the Cause of Death, 459/1973, Finnish Law).
The follow-up was complete.
2.4. Risk Factors
Core and most highly recommended supplementary variables for the study of UIA were available
for the present purpose [22], and the ELAPSS score [16] was recorded for each patient from variables at
the baseline. Hypertension at baseline was defined as a systolic pressure repeatedly >140 mm Hg,
a diastolic pressure >90 mm Hg, or use of antihypertensive medication. Cigarette smoking was
grouped as follows: never a smoker, formerly a regular cigarette smoker (quit before or during the
follow-up), or currently a cigarette smoker at the end of follow-up [9,15,17–19]. Alcohol consumption
was calculated as approximate grams of absolute ethanol consumed within one week (1 standard
drink = 12 g of alcohol) throughout the follow-up period. A family history of SAH was defined as
≥2 first-degree relatives with verified ruptured aneurysms.
2.5. Aneurysm Measurements
All angiographies and CTAs were examined by 2 experienced neuroradiologists who had no
knowledge of the patients’ case histories [1,9,15,17–21]. Discrepancies were resolved by consensus
opinion. The maximum diameters and locations of the UIAs were measured from standard projections
of 2D conventional angiograms at baseline; also recorded were the location and shape (round,
oval, irregular, or lobulate) of the UIA. Aneurysm growth rates were measured as the difference in
the maximum aneurysm diameter between the initial and follow-up angiographies from the same
projections or the initial angiography and the autopsy [15,17,18].
2.6. Statistical Analysis
The data were analyzed with IBM SPSS Statistics, version 25.0, for Windows (IBM Corp., Armonk,
NY, USA). The ELAPSS score variables at baseline were compared according to the UIA’s growth status
using Fisher’s exact test or the Pearson Chi-square test. Sum scores (expressed as mean ± standard
deviation (SD) and median with interquartile range (IQR)) were compared by means of t-tests and the
Mann–Whitney U-test.
Odds ratios (ORs) with 95% confidence intervals (CIs) of the risk factors for growth of UIA were
analyzed by multivariable unconditional logistic regression. A maximum-likelihood stepwise forward
elimination procedure was used, with selection of the variables to be added into the model on the basis
of the magnitudes of their probability values (p < 0.15). The new integer risk score points for aneurysm
growth were based on the regression coefficients in the final multivariable logistic regression model.
The areas under the curve (AUC) for the receiver operating curves (ROC) were calculated for both the
ELAPSS and the new growth scores. The C-statistic with 95% CIs was used to test how the total scores
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matched the observed rupture rates, the AUC between the scores being analyzed using the technique
of Hanley and McNeil [23]. A two-tailed p value < 0.05 was considered statistically significant.
2.7. Data Availability
Anonymized data not published within this article are available by request from any
qualified investigator.
3. Results
3.1. Patient Characteristics and Follow-Up
A total follow-up time of 87 patients was 1669 years between aneurysm measurements, and the
mean follow-up time for aneurysm size per patient was 19.2 years (median 21.7, range 1.2 to 51.0 years).
Twenty-seven patients (31%) suffered from a SAH and of them, 10 were fatal. The mean measurement
follow-up time in these 27 patients was 12.0 years (range 1.2 to 24.1 years), and that for the 60 patients
without a rupture was 22.4 years (1.3 to 51.0 years). All 27 UIAs which later ruptured had increased
in size by at least 1 mm and out of the largest UIAs of 60 patients without an aneurysm rupture,
13 increased by ≥1 mm.
3.2. ELAPSS Score and Aneurysm Growth
Factors of ELAPSS score stratified by aneurysm growth ≥1 mm are shown in Table 1. None of
separate factors differed by growth of UIA. The total score points were also similar between growth
groups. Since all patients were Finns exclusion of population from the ELAPSS score (7 points) had
no effect on significance levels. Odds ratio of ELAPSS score for aneurysm growth was 0.97 per unit
(95% CI, 0.90–1.04, p = 0.35).
Table 1. ELAPSS score stratified by long-term aneurysm growth.
Factor ELAPSS ScorePoints
Patients with Aneurysm Growth
(n = 40, 46%)
Patients wo Aneurysm Growth
(n = 47, 54%)
All Patients
(n = 87, 100%)
(E) Earlier SAH from another
aneurysm (%)
Yes 0 37 (47) 42 (53) 79 (100)
No 1 3 (38) 5 (63) 8 (100)
(L) Location of the aneurysm (%)
ICA/ACA/ACOM 0 9 (38) 15 (63) 24 (100)
MCA 3 21 (49) 22 (51) 43 (100)
PCOM/posterior 5 10 (50) 10 (50) 20 (100)
(A) Age (%)
< 60 years 0 40 (46) 47 (54) 87 (100)
>60 years (per 5 years) 1 0 0 0
(P) Population (%)
Finland 7 40 (46) 47 (54) 87 (100)
(S) Size of the aneurysm (%),
mm
1.0–2.9 0 8 (73) 3 (27) 11 (100)
3.0–4.9 4 17 (45) 21 (55) 38 (100)
5.0–6.9 10 8 (32) 17 (68) 25 (100)
7.0–9.9 13 5 (63) 3 (37) 8 (100)
≥10.0 22 2 (40) 3 (60) 5 (100)
(S) Shape of the aneurysm
Regular 0 37 (49) 39 (51) 76 (100)
Irregular 4 3 (27) 8 (73) 11 (100)
Mean ELAPSS score by
aneurysm growth (SD) 16.2 ± 6.0 17.9 ± 6.5 17.3 ± 6.2
Median ELAPSS score (IQR) 15 (12–20) 17 (12–21) 16 (12–20)
ELAPSS = Earlier subarachnoid hemorrhage, Location of the aneurysm, Age > 60 years, Population, Size of the
aneurysm, and Shape of the aneurysm; SAH = subarachnoid hemorrhage; ACOM = anterior communicating artery;
ACA = anterior cerebral artery; ICA = internal carotid artery; SD = standard deviation; IQR = interquartile
range (range between the 25th and 75th percentiles); MCA = middle cerebral artery; PCOM = posterior
communicating artery.
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3.3. Risk Factors for UIA Growth and the New Growth Score
All the ELAPSS factors with additional UIA locations, sex, hypertension, smoking, alcohol
consumption, and family history were tested with logistic regression analysis to identify the variables
which best predicted a future aneurysm growth. Women (adjusted OR 3.6, 95% CI 1.2–10.7, p = 0.019),
smoking at baseline (2.7, 0.93–7.6, p = 0.068), age <40 years (2.1, 0.8–5.5, p = 0.15) predicted best
long-term UIA growth. Smoking at the end of follow-up associated better with growth (3.2, 1.1–8.9,
p = 0.029) than smoking at baseline but it cannot be used in a new score since it is not a predictive
variable but represents better a long-term habit (Table 2). Total score sum was higher in those with a
UIA growth (p = 0.003). A new system for scoring of UIA growth was constructed from the regression
coefficients of the three variables: women 4 points, smoking 3 points, and age <40 years 2 points
(Table 2). Odds ratio of new scoring for aneurysm growth was 1.4 per unit (95% CI, 1.1–1.8, p = 0.006).
Table 2. New growth score stratified by long-term aneurysm growth.
Factor Aneurysm GrowthScore Points
Patients with Aneurysm Growth
(n = 40, 46%)
Patients without Aneurysm
Growth (n = 47, 54%)
All Patients
(n = 87, 100%)
Sex
Men 0 11 (32) 23 (68) 34 (100)
Women 4 29 (55) 24 (45) 53 (100)
Current cigarette
smoking at baseline
No 0 13 (35) 24 (65) 37 (100)
Yes 3 22 (50) 22 (50) 44 (100)
Current cigarette
smoking at end
of follow-up
No N/A 16 (34) 31 (66) 47 (100)
Yes N/A 19 (56) 15 (44) 34 (100)
Age
<40 years 2 25 (52) 23 (48) 48 (100)
≥40 years 0 15 (38) 24 (62) 39 (100)
Mean score by
aneurysm growth (SD) 5.9 (1.8) * 4.4 (2.4) 5.1 (2.3)
Median score (IQR) 5 (5–7) * 5 (3–6) 5 (4–6)
IQR = interquartile range (range between the 25th and 75th percentiles). Current smoking value was missing for 1
of the 47 patients without an aneurysm growth (2%) and 5 of the 40 with growth (13%). * p = 0.003 (p = 0.011 with
Mann–Whitney U-test), those aneurysm growths had a higher growth score; n = 81, those with missing smoking
habit were excluded from comparison.
3.4. The AUC for the ROCs of UIA Growth Scores
The AUC for the ROC of the new scoring for aneurysm growth was fair (0.662, SE 0.060, 95% CI
0.546–0.779, p = 0.013), and the optimal cut-off point was obtained at ≥4 vs. <4 points for sensitivity
(0.971) and specificity (0.304) (Figure 1). The AUC for the ROC of simple scoring (points 0 vs. 1 for all
three variables) was almost the same (AUC 0.658, SE 0.060, 95% CI 0.540–0.776, p < 0.015). The optimal
cut-off point was obtained with the sum score at ≥2 vs. <2 points with a sensitivity (0.771) and
specificity (0.457). The AUC of the ELAPSS score was fail (0.474, SE 0.066, 95% CI 0.345–0.603, p = 0.69),
and the optimal cut-off point was obtained at ≥5 vs. <5 points for sensitivity (0.829) and specificity
(0.217) (Figure 1). So, false positive rate was high. The difference between the scores for AUCs was
significant (p < 0.05). The AUC of ELAPSS, which also included patients with missing values for
smoking was 0.450 (SE 0.063, 95% CI 0.327–0.573, p = 0.42) and the cut-off point at ≥5 vs. <5 points
yielded sensitivity 0.800 and specificity 0.213 (Table 3).
J. Clin. Med. 2020, 9, 3339 6 of 10
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 10 
 
values for smoking was 0.450 (SE 0.063, 95% CI 0.327–0.573, p = 0.42) and the cut-off point at ≥5 vs. <5 
points yielded sensitivity 0.800 and specificity 0.213 (Table 3). 
 
Figure 1. Receiver operating characteristic curves of growth scores for predicting the long-term 
growth of unruptured intracranial aneurysms. See text for statistics of the curves. The difference 
between the scores for area under the curve (AUC) was significant (p < 0.05). ROC = Receiver 
operating characteristic. 
Table 3. Aneurysm growth scores and number of patients with an aneurysm growth. 
Aneurysm Growth Risk 
Score Points 
Patients with Aneurysm 
Growth (%) 
Patients without 
Aneurysm Growth (%) 
No. of 
Patients (%) 
ELAPSS score *    
0–4 (7–11) 8 (44) 10 (56) 18 (100) 
5–7 (12–14) 12 (57) 9 (43) 21 (100) 
8–11 (15–18) 7 (50) 7 (50) 14 (100) 
12–16 (19–23) 8 (35) 15 (65) 23 (100) 
17–30 (24–37) 5 (45) 6 (55) 11 (100) 
Total 40 (46) 47 (54) 87 (100) 
Present score †    
0–3 1 (7) 14 (93) 15 (100) 
4 7 (50) 7 (50) 14 (100) 
5–6 16 (48) 17 (52) 33 (100) 
7–9 11 (58) 8 (42) 19 (100) 
Total 35 (43) 46 (57) 81 (100) 
* ELAPSS score groups are shown both with (in parentheses) and without Finnish population points 
(7 points) which has no effect on significance levels. The difference between ELAPSS scores and 
aneurysm growth were not significant. Cut-off point at ≥5 vs. <5 points yielded sensitivity 0.800 and 
specificity 0.213. † p < 0.01, for differences between aneurysm growth and scoring groups. Use of ≥4 
vs. <4 points in the present score for aneurysm growth gives a sensitivity of 0.971 and specificity of 
0.304. 
Figure 1. Receiver operating characteristic curves of growth scores for predicting the long-term growth
of unruptured intracranial aneurysms. See text for statistics of the curves. The difference between the
scores for area under the curve (AUC) was significant (p < 0.05). ROC = Receiver operating characteristic.
Table 3. Aneurysm growth scores and number of patients with an aneurysm growth.
Aneurysm Growth Risk
Score Points
Patients with
Aneurysm Growth (%)
Patients without
Aneurysm Growth (%) No. of Patients (%)
ELAPSS score *
0–4 (7–11) 8 (44) 10 (56) 18 (100)
5–7 (12–14) 12 (57) 9 (43) 21 (100)
8–11 (15–18) 7 (50) 7 (50) 14 (100)
12–16 (19–23) 8 (35) 15 (65) 23 (100)
17–30 (24–37) 5 (45) 6 (55) 11 (100)
Total 40 (46) 47 (54) 87 (100)
Present score †
0–3 1 (7) 14 (93) 15 (100)
4 7 (50) 7 (50) 14 (100)
5–6 16 (48) 17 (52) 33 (100)
7–9 11 (58) 8 (42) 19 (100)
Total 35 (43) 46 (57) 81 (100)
* ELAPSS score groups are shown both with (in parentheses) and without Finnish population points (7 points)
which has no effect on significance levels. The difference between ELAPSS scores and aneurysm growth were not
significant. Cut-off point at ≥5 vs. <5 points yielded sensitivity 0.800 and specificity 0.213. † p < 0.01, for differences
between aneurysm growth and scoring groups. Use of ≥4 vs. <4 points in the present score for aneurysm growth
gives a sensitivity of 0.971 and specificity of 0.304.
4. Discussion
Th growth score of UIAs btained from this prospective study with an almost lifelong f llow-up
and a very l w treatment selection bias s ggests that growth of UIAs among patients of working
age can be estimated quite reliably with only three variables at baseline. Female sex, patient age
(<40 years), and cigarette smoking determine the risk of UIA growth significantly better than does the
ELAPSS score.
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Simultaneously with the discovery of increasing numbers of UIAs, it is likely that the indications
for treatment will decrease, because of the decline in the prevalence of smoking and the incidence
of SAH [7,8] and because of the discovery of incidental UIAs in older people more than previously.
These patients are also less likely to be smokers or to have higher treatment risks because of age.
The cost-effectiveness ratio of UIA treatment is thus increasing. To obtain more reliability in the
treatment decision, follow-up angiographic investigations have become more prevalent to search
for UIAs that grow. Growing of UIAs correlates with later rupture, particularly in a long-term
follow-up [14,15,17,18].
According to the results of two recent meta-analyses of aneurysm growth, female sex, cigarette
smoking at baseline, aneurysm size, posterior circulation aneurysms, and possibly age, hypertension,
and aneurysm multiplicity may increase the risk of UIA growth, while prior SAH and a family history
of aneurysms do not [13,14]. There was a substantial heterogeneity for risk factors between studies,
except in the case of female sex, smoking at baseline, and hypertension. High data quality (low risk of
study bias), Japanese and Finnish populations, and prospective study design were associated with
decreased growth risk [13]. The results of these meta-analyses were subject to treatment selection
of UIAs and follow-ups were mostly short extending only approximately for 3–5 years. Because of
treatment selections most UIA growth studies have shown low rupture rates [13,14]. High risk UIAs
(large UIAs in younger patients and smokers) are usually treated already at baseline without any
follow-up [12].
The present study with an almost lifelong follow-up of UIA patients also included patients with a
high UIA rupture risk as was seen in the relatively high UIA growth rate among patients of working
age. Expectedly, UIA growth score obtained from the present score included partly same factors as
treatment score based on risk factors of UIA rupture [21]. The treatment score (the AUC for the ROC
0.755) predicted slightly better aneurysm rupture than did present growth score for the growth of UIA.
Both these scores included cigarette smoking, patient age <40 years, and female gender, the latter being
of borderline statistical significance in the treatment score. Aneurysm size and some locations were
included in the treatment score but not in the growth score. This is not surprising since e.g., aneurysms
in the anterior communicating artery are more prone to rupture with a smaller size than those in
middle cerebral artery which grow more before rupture [15].
Previously published results from this cohort [15,17,18] have been reported to have the best
data quality and the lowest bias of all UIA growth studies to date, in spite of reporting the lowest
approximate annual incidence of growth [13,14]. ELAPSS score study [16] with a relatively short
follow-up (median 2.5 years) has some contradictory results with PHASES score study which was
planned to predict aneurysm rupture risk (e.g., for previous SAH and some aneurysm locations) [12].
Although ELAPSS score study is a pooled individual patient data meta-analysis its results also conflict
with those of two other recent meta-analyses for sex, age, previous SAH, populations, and some
aneurysm locations [13,14]. Predictors for aneurysm growth were Earlier subarachnoid hemorrhage
(decrease risk!), Location of the aneurysm, Age > 60 years, Population, Size of the aneurysm, and Shape
of the aneurysm (ELAPSS). Of the total 1507 patients with UIAs only 18 patients (1.2%) had an
aneurysm rupture, and of 257 growing UIAs only 8 (3.1%) ruptured. Cigarette smoking which has been
most significant risk factor for UIA growth and SAH [24,25] was not analyzed in ELAPSS score study.
UIA growth in long-term follow-up also correlated better with its rupture [14,15]. Mean follow-up
among patients of working age between diagnosis and rupture in the present study was >10 years.
Routine follow-up angiography during 1–3 years after the diagnosis seems also to be unreliable since
aneurysm may be stable >20 years, then grow 1 mm and rupture [15,18].
Selection criteria for aneurysm occlusion treatment and conservative follow-up with/without
control angiograms in participating centers in the ELAPSS score study were heterogeneous. In some
countries, small UIAs in elderly are routinely followed radiologically. In Finland only those patients
with uncertainty for treatment are followed up on clinical-based criteria. This was seen also in the
ELAPSS score study where patients with angiographic follow-up in Finland were significantly younger
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than elsewhere and these patients are known to be more likely smokers and have higher UIA growth
risk [13,15,17,18]. This has leaded arbitrarily to a high ELAPSS score among Finns although in one
meta-analysis, the growth rate of their UIAs was even lower [13]. ELAPSS score describes preferably
the growth of low rupture risk UIAs in patients left to conservative treatment. This was also seen in
the low aneurysm rupture rate in the ELAPSS score study. These results are difficult to be generalized
to all patients with UIAs.
The strengths of this study lie in the complete and almost lifelong follow-up of patient of working
age and the very limited treatment selection bias [9,15,18]. Correspondingly, a previous aneurysm
growth study based on this cohort [15,17,18] was considered to be of high study quality and have
low sources of bias relative to other UIA growth studies [13,14]. Although Finnish people have been
considered to be subject to a higher risk of aneurysm rupture, the incidence of SAH is no higher
in Finland than elsewhere when standardized for the study design with its inclusion and exclusion
criteria, the accuracy of diagnosis, and the sex and age distributions of the population [8]. The Nordic
countries seem to have similar incidences of SAH. A recent twin study has shown that the contribution
of genetic factors as the cause of SAH appears to be slight, and the main causal factor seems to be
cigarette smoking [26].
A limitation of this study is the relatively small sample size, despite a long total follow-up time
as compared with other large prospective study populations, which on the other hand, had shorter
follow-ups and a high treatment selection bias. Patients with a prior history of SAH have not
been shown to have a significantly higher risk of aneurysm rupture or growth than others when
confounding factors are taken into account [12]. In this study, all initial UIA measurements were
obtained from two-dimensional conventional angiograms, which may yield less accurate measures
than three-dimensional angiograms. For UIA growth measurement the same projections were done as
was done in initial angiograms.
The present simple, rapid scoring system for UIA growth is significantly better and easier to use
than the ELAPSS score. This new growth score contains also the same factors than the treatment score
obtained from this cohort. The latter score is directed to evaluate rupture risk of UIAs and its value for
prediction is somewhat better than that for growth score. The treatment score is preferable in clinical
practice for treatment decision and it likely reduces need of follow-up angiographies.
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